For individuals considering prescription-based weight loss treatment, understanding the role of GLP-1 medications is an important first step before deciding whether to proceed with a medical consultation and personalised treatment plan
Before starting treatment, I always discuss: Monthly medication costs Duration of treatment Long-term affordability Follow-up consultation costs Lifestyle sustainability One important point patients often overlook is that obesity is usually a chronic condition
Tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, reports injection site reaction rates of approximately 1.7-2.2% in its FDA prescribing information, similar to semaglutide
This neurological shift typically precedes any weight loss on the scale, which is an important expectation to set for new users
[17] Eli Lilly and Company, 'Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)', ClinicalTrials.gov identifier NCT06260722